


Prescribing Pathway - PCSK9 Inhibitors for the management of primary hypercholesterolaemia (heterozygous-familial and non-familial) and mixed dyslipidaemia (NICE TA 393 and 394)



LDL-C persistently above thresholds (defined locally as at least two consecutive LDL-C readings over a minimum 3 month period)

Consider initiating either:

Alirocumab: 75mg or 150mg s/c injection every two weeks
OR
Evolocumab: 140mg s/c injection every two weeks

*High risk of cardiovascular disease is defined as a history of any of the following: acute coronary syndrome (such as myocardial infarction or unstable angina requiring hospitalisation), coronary or other arterial revascularisation procedures, chronic heart disease, ischaemic stroke, peripheral arterial disease.

**Very high risk of cardiovascular disease is defined as recurrent cardiovascular events or cardiovascular events in more than 1 vascular bed (that is, polyvascular disease).